SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company focused on developing multi-specific, fully human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders. The company's website is www.sabbiotherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SAB Biotherapeutics, Inc. does
In the company’s own words
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company focused on developing multi-specific, fully human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders. The company's website is www.sabbiotherapeutics.com.
The company's lead product candidate, SAB-142, is a potentially disease-modifying immunotherapy in clinical development for treating autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin designed to target multiple immune cells involved in destroying pancreatic beta cells. The company initiated its registrational Phase 2b clinical trial, called SAFEGUARD, in the third quarter of 2025, with the first patient dosed in December 2025. Topline data from this study is expected in the second half of 2027.
SAB Biotherapeutics operates a proprietary production platform based on transchromosomal cattle, or Tc-Bovine technology, which enables the generation of disease-targeted, fully human immunoglobulins in large quantities without requiring human donors or convalescent plasma. This platform represents a significant technological advancement, as it is believed to be the only technology capable of producing such antibodies at commercial scale. The company's genetic engineering approach functionally replaces bovine immunoglobulin with human antibodies produced from engineered human artificial chromosomes, creating a diverse repertoire of high-potency, multi-specific antibodies.
The company maintains manufacturing and research operations in Sioux Falls, South Dakota, including two plasma fractionation and purification facilities at 50-liter and 200-liter scales, as well as laboratory facilities for drug discovery, product development, and clinical manufacturing. SAB Biotherapeutics also operates dedicated animal facilities accredited by the American Association for Accreditation of Laboratory Animal Care to house and manage its Tc-Bovine herd.
The company's intellectual property portfolio includes over fifty issued patents or pending applications covering its HAC vector technology and manufacturing methods, with global patent protection expected to extend to 2041 and beyond. SAB Biotherapeutics competes in the biopharmaceutical industry against larger pharmaceutical companies, specialty biotechnology firms, and academic research institutions developing treatments for autoimmune and immune-mediated disorders.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- MIAMI BEACH, FL
- Fiscal year end
- December
- CIK
- 1833214
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SAB Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SAB Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SAB Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SAB Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SAB Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”